Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference - 24/04/13
Correspondence to: Alice B. Gottlieb, MD, PhD, 800 Washington St, Box 114, Biewend Bldg, Tufts Medical Center, Boston, MA 02111.Abstract |
Background |
Cyclosporine is a valuable option for the treatment of psoriasis. This report summarizes studies regarding the use of cyclosporine since the last guidelines were published in 1998.
Objective |
A task force of the National Psoriasis Foundation Medical Board was convened to evaluate treatment options. Our aim was to achieve a consensus on new updated guidelines for the use of cyclosporine in the treatment of psoriasis.
Methods |
Reports in the literature were reviewed regarding cyclosporine therapy.
Limitations |
There are few evidence-based studies on the treatment of psoriasis with cyclosporine.
Results |
A consensus was achieved on the use of cyclosporine in psoriasis including specific recommendations on dosing, monitoring, and use of cyclosporine in special situations. The consensus received approval from members of the National Psoriasis Foundation Medical Board.
Conclusions |
Cyclosporine is a safe and effective drug for the treatment of psoriasis. It has a particularly useful role in managing psoriatic crises, treating psoriasis unresponsive to other modalities, bridging to other therapies, and treating psoriasis within a rotational scheme of other medications. Appropriate patient selection and monitoring will significantly decrease the risks of side effects.
Le texte complet de cet article est disponible en PDF.Key words : cyclosporine, psoriasis, psoriatic arthritis, review, therapy
Abbreviations used : HCV, IL, PASI, PUVA, TNF, UV
Plan
| Funding sources: None. |
|
| Disclosure: Dr Gottlieb served on the advisory board of and was a speaker and consultant for Amgen Inc and Wyeth Pharmaceuticals; has consulting/advisory board agreements with Beiersdorf, Abbott, Sankyo, Kemia, Actelion, Novo Nordisk, Immune Control, Dermipsor, Can-Fite, Celgene, Centocor Inc, Bristol Myers Squibb, Warne Chilcott, Roche, Medarex, Celera, UCB, Almirall, RxClinical, Medacorp, and Incyte; and has consulted for Magen, PureTech, and Teva. She received grants from Amgen, Wyeth Pharmaceuticals, Immune Control, Celgene, Centocor Inc, Incyte, and Pharmacare. Almost all income has been paid to her employer directly. Dr Lebwohl served on the advisory board of and was speaker for Abbott Labs, Amgen, Astellas, Centocor, Galderma, Genentech, Stiefel, and Warner Chilcott, receiving honoraria; served on the advisory board of and was consultant and speaker for PharmaDerm, receiving honoraria; was speaker for Novartis and Ranbaxy, receiving honoraria; was consultant for Biogen, UCB, DermiPsor, Isotechnika, Sanofi-Aventis, Triax, and York Pharma, receiving honoraria; and served on the advisory board of Medicis and Pfizer, receiving honoraria. Members of Dr Lebwohl’s department own patents on short-contact tazarotene, topical genistein, and use of the excimer laser for vitiligo. Dr Elewski was an investigator receiving grants from Abbott, Amgen, Centocor, Ortho Neutrogenia, and Stiefel; was a consultant receiving honoraria from Intendis and NanoBio; and was a consultant and investigator receiving honoraria and grants from Schering Plough. Dr Elewski’s department received compensation that does not benefit her directly from Amgen, Novartis, Mediquest, Astellas, Abbott, Barrier, and Centocor. Dr Rosmarin disclosed no relevant conflicts of interest. |
|
| Reprints not available from the authors. |
Vol 62 - N° 5
P. 838-853 - mai 2010 Retour au numéro
Article précédent
- Clinical and pathologic characteristics of disseminated cutaneous coccidioidomycosis
- John B. Carpenter, Jacob S. Feldman, William H. Leyva, David J. DiCaudo
- Tanning and skin cancer
- Jacqueline M. Junkins-Hopkins
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?